Therapy for osteoarthritis in undifferentiated connective tissue dysplasia

E.B. Klester, L.A. Plinokosova

Altay State Medical University, Barnaul

Aim: to assess the efficacy and tolerability of AMBENE^® Bio for knee osteoarthritis secondary to undifferentiated connective tissue dysplasia.

Patients and Methods: this study enrolled 150 women with established gonarthrosis (Kellgren–Lawrence grade 1–2) secondary to undifferentiated connective tissue dysplasia (median age 45.7 years, median disease duration 3.2 years) who received NSAIDs and AMBENE^® Bio. Monthly monitoring included physical examination, assessment using visual analogue scale (VAS) and self-assessment (WOMAC) over a 12-month period.

Results: after one month of treatment, pain severity at rest and movement-evoked pain severity measured by VAS decreased in 73.33% and 62% of women, respectively. The WOMAC score reduced from 27.57±6.35 to 6.12±1.35 (p<0.01). Six months after completion the first treatment course, pain severity increased, i.e., overall WOMAC score significantly increased to 17.32±2.12 (p<0.01). Repeated treatment course with AMBENE^® Bio reduced pain severity at rest and movement-evoked pain severity measured by VAS reduced in 88% and 74% of women. Overall WOMAC score reduced to 4.12±1.01 (p<0.01). Six months after re-treatment course with AMBENE^® Bio, pain at rest and movement-evoked pain reappeared only in 15.33% and 30% of women, respectively (measured by VAS). Overall WOMAC score was 8.14±1.78 (p<0,01).

Conclusion: AMBENE^® Bio reduces pain severity and need for NSAIDs. Re-treatment courses improve symptoms and prolong remission.

Keywords: undifferentiated connective tissue dysplasia, osteoarthritis, gonarthrosis, chondroprotectors, visual analogue scale, WOMAC, osteoarthritis treatment, non-steroidal anti-inflammatory drugs.

For citation: Klester E.B., Plinokosova L.A. Therapy for osteoarthritis in undifferentiated connective tissue dysplasia. RMJ. 2022;3:40–42.